# US 2008/0269347 A1 · Epinephrine formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269347 A1
- Document ID: US20080269347A1
- Status: Published application
- Kind: A1
- Application number: 11/864,234
- Filed: 2007-09-28
- Published: 2008-10-30
- Earliest claimed: 2006-09-28
- Assignees: Azopharma, Inc.
- Inventors: Jon Bruss; John McCarty; Blair West
- Web page: https://patentgrep.com/patent/US20080269347A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally concerns an epinephrine formulation that has enhanced stability. In particular embodiments, the formulation is an injectable formulation. In specific aspects, the formulation comprises epinephrine, EDTA, and one or more of an antioxidant such as cysteine, citric acid, acetylcysteine, or thioglycerol. The formulations are suitable for any medical condition that is in need of epinephrine, although in specific embodiments the medical condition is anaphylaxis, asthma, or cardiac arrest.

## Claims

### Claim 1

An injectable pharmaceutical composition comprising epinephrine, EDTA, and at least one antioxidant, wherein the antioxidant is selected from the group consisting of cysteine, citric acid, thioglycerol, acetylcysteine, and a combination thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the antioxidant is cysteine.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the antioxidant is citric acid.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the antioxidant is thioglycerol.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the antioxidant is acetylcysteine.

### Claim 6

A kit, comprising:
a pharmaceutical composition comprising epinephrine, EDTA, and at least one antioxidant, wherein the antioxidant is selected from the group consisting of cysteine, citric acid, thioglycerol, acetylcysteine, and a combination thereof; and
an injection apparatus.

### Claim 7 (depends on 6)

The kit of claim 6, wherein said pharmaceutical composition is housed in the injection apparatus or is housed separate from the injection apparatus.

### Claim 8 (depends on 6)

The kit of claim 6, wherein said injection apparatus is further defined as being selected from the group consisting of a syringe and an autoinjector.

### Claim 9 (depends on 6)

The kit of claim 6, wherein the antioxidant is cysteine.

### Claim 10 (depends on 6)

The kit of claim 6, wherein the antioxidant is citric acid.

### Claim 11 (depends on 6)

The kit of claim 6, wherein the antioxidant is thioglycerol.

### Claim 12 (depends on 6)

The kit of claim 6, wherein the antioxidant is acetylcysteine.

### Claim 13

A method of improving at least one symptom of an epinephrine-requiring medical condition in an individual in need thereof, comprising injecting into the individual a formulation comprising:
epinephrine;
EDTA;
a pharmaceutically acceptable carrier; and
at least one antioxidant, wherein the at least one antioxidant is selected from the group consisting of cysteine, citric acid, thioglycerol, acetylcysteine, and a combination thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said formulation is housed in an injection apparatus or is housed separately from an injection apparatus.

### Claim 15 (depends on 13)

The method of claim 13, wherein said injecting is by an autoinjector.

### Claim 16 (depends on 13)

The method of claim 13, wherein the antioxidant is cysteine.

### Claim 17 (depends on 13)

The method of claim 13, wherein the antioxidant is citric acid.

### Claim 18 (depends on 13)

The method of claim 13, wherein the antioxidant is thioglycerol.

### Claim 19 (depends on 13)

The method of claim 13, wherein the antioxidant is acetylcysteine.

### Claim 20 (depends on 13)

The method of claim 13, wherein the injection is in the thigh of the individual, is intracardially into the individual, or is endotracheally into the individual.

### Claim 21

A method of treating anaphylaxis in an individual comprising injecting into the individual a formulation, said formulation comprising:
epinephrine;
EDTA;
a pharmaceutically acceptable carrier; and
at least one antioxidant, wherein the at least one antioxidant is selected from the group consisting of cysteine, citric acid, thioglycerol, acetylcysteine, and a combination thereof, wherein the formulation is injected by an auto-injector.

### Claim 22

A method of treating a pediatric individual in need of treatment for anaphylaxis comprising injecting into the individual a formulation comprising:
epinephrine;
EDTA; and
at least one antioxidant, wherein the at least one antioxidant is selected from the group consisting of cysteine, citric acid, thioglycerol, acetylcysteine, and a combination thereof.
